Mr Mark Salji
- Honorary Clinical Senior Lecturer (School of Cancer Sciences)
email:
Mark.Salji@glasgow.ac.uk
Queen Elizabeth University Hospital, 1345 Govan Rd, Glasgow, G51 4TF
https://orcid.org/0000-0003-4261-3086Publications
2023
Rushworth, L. K. et al. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131(2), pp. 236-243. (doi: 10.1111/bju.15851) (PMID:35844167)
2022
Freckmann, E. C. et al. (2022) Traject3d allows label-free identification of distinct co-occurring phenotypes within 3D culture by live imaging. Nature Communications, 13, 5317. (doi: 10.1038/s41467-022-32958-x) (PMID:36085324) (PMCID:PMC9463449)
Salji, M. J. et al. (2022) Multi-omics and pathway analysis identify potential roles for tumour n-acetyl aspartate accumulation in murine models of castration resistant prostate cancer. iScience, 25(4), 104056. (doi: 10.1016/j.isci.2022.104056) (PMID:35345457) (PMCID:PMC8957019)
O’Connell, S. P. et al. (2022) A model to detect significant prostate cancer integrating urinary peptide and extracellular vesicle RNA data. Cancers, 14(8), 1995. (doi: 10.3390/cancers14081995)
Gaba, F., Tipping, W. J., Salji, M. , Faulds, K., Graham, D. and Leung, H. Y. (2022) Raman spectroscopy in prostate cancer: techniques, applications and advancements. Cancers, 14(6), 1535. (doi: 10.3390/cancers14061535) (PMID:35326686) (PMCID:PMC8946151)
Blomme, A. et al. (2022) THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 14(3), e14764. (doi: 10.15252/emmm.202114764) (PMID:35014179) (PMCID:PMC8899912)
Adam, C., Bray, T. L., Pérez-López, A. M., Tan, E. H., Rubio-Ruiz, B., Baillache, D. J., Houston, D. R., Salji, M. J. , Leung, H. Y. and Unciti-Broceta, A. (2022) A 5-FU precursor designed to evade anabolic and catabolic drug pathways and activated by Pd chemistry in vitro and in vivo. Journal of Medicinal Chemistry, 65(1), pp. 552-561. (doi: 10.1021/acs.jmedchem.1c01733) (PMID:34979089)
2021
Martinez, R. S. et al. (2021) SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer. Cancer Research, 81(13), pp. 3664-3678. (doi: 10.1158/0008-5472.CAN-20-3694) (PMID:33985973)
Ntala, C. et al. (2021) Analysis of prostate cancer tumor microenvironment identifies reduced stromal CD4 effector T-cell infiltration in tumors with pelvic nodal metastasis. European Urology Open Science, 29, pp. 19-29. (doi: 10.1016/j.euros.2021.05.001) (PMID:34337530) (PMCID:PMC8317840)
Cangiano, M. et al. (2021) Gene regulation network analysis on human prostate orthografts highlights a potential role for the JMJD6 regulon in clinical prostate cancer. Cancers, 13(9), 2094. (doi: 10.3390/cancers13092094) (PMID:33925994) (PMCID:PMC8123677)
2020
Blomme, A. et al. (2020) 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nature Communications, 11, 2508. (doi: 10.1038/s41467-020-16126-7) (PMID:32427840) (PMCID:PMC7237503)
Loveridge, C. J. et al. (2020) BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene, 39, pp. 1797-1806. (doi: 10.1038/s41388-019-1106-x) (PMID:31740786) (PMCID:PMC7033044)
2018
Salji, M. , Hendry, J., Patel, A., Ahmad, I. , Nixon, C. and Leung, H. Y. (2018) Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer. European Urology Focus, 4(6), pp. 858-866. (doi: 10.1016/j.euf.2017.01.019) (PMID:28753854) (PMCID:PMC6314965)
Bray, T. L., Salji, M. , Brombin, A., Pérez-López, A. M., Rubio-Ruiz, B., Galbraith, L. C.A., Patton, E. E., Leung, H. Y. and Unciti-Broceta, A. (2018) Bright insights into palladium-triggered local chemotherapy. Chemical Science, 9(37), pp. 7354-7361. (doi: 10.1039/c8sc02291g) (PMID:30542538) (PMCID:PMC6237126)
Patel, R. et al. (2018) Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1. EMBO Molecular Medicine, 10(4), e8347. (doi: 10.15252/emmm.201708347) (PMID:29540470) (PMCID:PMC5887544)
2017
Winchester, C. L., Salji, M. J. and Kasivisvanathan, V. (2017) Gathering preliminary data. Journal of Clinical Urology, 10(6), pp. 568-572. (doi: 10.1177/2051415817724713)
Loveridge, C. J. et al. (2017) Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity. Scientific Reports, 7, 13241. (doi: 10.1038/s41598-017-13346-8) (PMID:29038439) (PMCID:PMC5643304)
2016
Salji, M. , Ahmad, I. and Winchester, C. (2016) Non-clinical research – laboratory based. Journal of Clinical Urology, 9(6), pp. 362-364. (doi: 10.1177/2051415816650134)
Winchester, C. and Salji, M. (2016) Writing a literature review. Journal of Clinical Urology, 9(5), pp. 308-312. (doi: 10.1177/2051415816650133)
Ahmad, I. et al. (2016) Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 113(29), pp. 8290-8295. (doi: 10.1073/pnas.1601571113) (PMID:27357679) (PMCID:PMC4961202)
Articles
Rushworth, L. K. et al. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131(2), pp. 236-243. (doi: 10.1111/bju.15851) (PMID:35844167)
Freckmann, E. C. et al. (2022) Traject3d allows label-free identification of distinct co-occurring phenotypes within 3D culture by live imaging. Nature Communications, 13, 5317. (doi: 10.1038/s41467-022-32958-x) (PMID:36085324) (PMCID:PMC9463449)
Salji, M. J. et al. (2022) Multi-omics and pathway analysis identify potential roles for tumour n-acetyl aspartate accumulation in murine models of castration resistant prostate cancer. iScience, 25(4), 104056. (doi: 10.1016/j.isci.2022.104056) (PMID:35345457) (PMCID:PMC8957019)
O’Connell, S. P. et al. (2022) A model to detect significant prostate cancer integrating urinary peptide and extracellular vesicle RNA data. Cancers, 14(8), 1995. (doi: 10.3390/cancers14081995)
Gaba, F., Tipping, W. J., Salji, M. , Faulds, K., Graham, D. and Leung, H. Y. (2022) Raman spectroscopy in prostate cancer: techniques, applications and advancements. Cancers, 14(6), 1535. (doi: 10.3390/cancers14061535) (PMID:35326686) (PMCID:PMC8946151)
Blomme, A. et al. (2022) THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 14(3), e14764. (doi: 10.15252/emmm.202114764) (PMID:35014179) (PMCID:PMC8899912)
Adam, C., Bray, T. L., Pérez-López, A. M., Tan, E. H., Rubio-Ruiz, B., Baillache, D. J., Houston, D. R., Salji, M. J. , Leung, H. Y. and Unciti-Broceta, A. (2022) A 5-FU precursor designed to evade anabolic and catabolic drug pathways and activated by Pd chemistry in vitro and in vivo. Journal of Medicinal Chemistry, 65(1), pp. 552-561. (doi: 10.1021/acs.jmedchem.1c01733) (PMID:34979089)
Martinez, R. S. et al. (2021) SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer. Cancer Research, 81(13), pp. 3664-3678. (doi: 10.1158/0008-5472.CAN-20-3694) (PMID:33985973)
Ntala, C. et al. (2021) Analysis of prostate cancer tumor microenvironment identifies reduced stromal CD4 effector T-cell infiltration in tumors with pelvic nodal metastasis. European Urology Open Science, 29, pp. 19-29. (doi: 10.1016/j.euros.2021.05.001) (PMID:34337530) (PMCID:PMC8317840)
Cangiano, M. et al. (2021) Gene regulation network analysis on human prostate orthografts highlights a potential role for the JMJD6 regulon in clinical prostate cancer. Cancers, 13(9), 2094. (doi: 10.3390/cancers13092094) (PMID:33925994) (PMCID:PMC8123677)
Blomme, A. et al. (2020) 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nature Communications, 11, 2508. (doi: 10.1038/s41467-020-16126-7) (PMID:32427840) (PMCID:PMC7237503)
Loveridge, C. J. et al. (2020) BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene, 39, pp. 1797-1806. (doi: 10.1038/s41388-019-1106-x) (PMID:31740786) (PMCID:PMC7033044)
Salji, M. , Hendry, J., Patel, A., Ahmad, I. , Nixon, C. and Leung, H. Y. (2018) Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer. European Urology Focus, 4(6), pp. 858-866. (doi: 10.1016/j.euf.2017.01.019) (PMID:28753854) (PMCID:PMC6314965)
Bray, T. L., Salji, M. , Brombin, A., Pérez-López, A. M., Rubio-Ruiz, B., Galbraith, L. C.A., Patton, E. E., Leung, H. Y. and Unciti-Broceta, A. (2018) Bright insights into palladium-triggered local chemotherapy. Chemical Science, 9(37), pp. 7354-7361. (doi: 10.1039/c8sc02291g) (PMID:30542538) (PMCID:PMC6237126)
Patel, R. et al. (2018) Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1. EMBO Molecular Medicine, 10(4), e8347. (doi: 10.15252/emmm.201708347) (PMID:29540470) (PMCID:PMC5887544)
Winchester, C. L., Salji, M. J. and Kasivisvanathan, V. (2017) Gathering preliminary data. Journal of Clinical Urology, 10(6), pp. 568-572. (doi: 10.1177/2051415817724713)
Loveridge, C. J. et al. (2017) Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity. Scientific Reports, 7, 13241. (doi: 10.1038/s41598-017-13346-8) (PMID:29038439) (PMCID:PMC5643304)
Salji, M. , Ahmad, I. and Winchester, C. (2016) Non-clinical research – laboratory based. Journal of Clinical Urology, 9(6), pp. 362-364. (doi: 10.1177/2051415816650134)
Winchester, C. and Salji, M. (2016) Writing a literature review. Journal of Clinical Urology, 9(5), pp. 308-312. (doi: 10.1177/2051415816650133)
Ahmad, I. et al. (2016) Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 113(29), pp. 8290-8295. (doi: 10.1073/pnas.1601571113) (PMID:27357679) (PMCID:PMC4961202)